Agreement Combines Technologies in Epigenetics Research

A new partnership will see the integration of Cambridge Epigenetix’s (CEGX) TrueMethyl technology for oxidative bisulfite sequencing (oxBS-Seq) with NuGEN’s innovative NGS library preparation kits. The agreement will enable CEGX to focus on its epigenetic biomarker discovery programmes, both in-house and in partnership with leading biopharma companies and will further strengthen NuGEN’s epigenetics portfolio of whole genome Methyl-seq, Reduced Representation Bisulphate Sequencing (RRBS) and patented SPET target enrichment systems.

Jason Mellad, CEO at Cambridge Epigenetix, commented: “This partnership will enable both CEGX and NuGEN to leverage our strengths to facilitate advances in the epigenetics field. CEGX is committed to realising the promise of epigenetics through the development of improved, minimally invasive diagnostic and prognostic tests for accurate and early detection of a range of diseases, including cancer. We are working with leading biopharma companies as well as progressing our own high-value internal programmes, applying our expertise and advanced proprietary technology for robust biomarker identification, particularly from liquid biopsy samples. NuGEN’s reach and reputation for delivering high-quality genomics solutions to the market makes them the ideal partner to further develop TrueMethyl technology to deliver a range of new products to enhance epigenetics research.”

Nitin Sood, CEO at NuGEN Technologies, said: “We are delighted to be working with CEGX to provide the tools to improve the understanding and appreciation of epigenetics in cellular function. The goal of all of our products has always been to maximize the information that our customers obtain from their nucleic acid samples. By combining the TrueMethyl oxBS technology with our NGS library preparation kits, we will provide our customers with whole genome and targeted methylation products to unlock the tremendous potential of epigenetics. The combination provides access to more detailed, higher resolution epigenetic information in an integrated, cost-effective solution.

New products resulting from this partnership are anticipated by the end of the year and will be available directly from NuGEN. TrueMethyl products should still be ordered through CEGX until further notice.